Last update 24 Jun 2024

Apraglutide

Overview

Basic Info

Drug Type
Synthetic peptide
Synonyms
GLP2 analouge, FE 203799, FE-203799
+ [3]
Target
Mechanism
GLP-2R agonists(Glucagon-like peptide 2 receptor agonists)
Originator Organization
Inactive Organization
Drug Highest PhasePhase 3
First Approval Date-
RegulationOrphan Drug (US), Orphan Drug (EU)

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Intestinal FailurePhase 3
US
26 Jan 2021
Intestinal FailurePhase 3
JP
26 Jan 2021
Intestinal FailurePhase 3
AR
26 Jan 2021
Intestinal FailurePhase 3
BE
26 Jan 2021
Intestinal FailurePhase 3
CZ
26 Jan 2021
Intestinal FailurePhase 3
DK
26 Jan 2021
Intestinal FailurePhase 3
FR
26 Jan 2021
Intestinal FailurePhase 3
DE
26 Jan 2021
Intestinal FailurePhase 3
HU
26 Jan 2021
Intestinal FailurePhase 3
IL
26 Jan 2021
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
164
yxbitmbssl(ucwlzknswe) = mshjeaxhkc xncdkreiho (emeelhgkpa )
Met
Positive
21 May 2024
Phase 3
163
phvdujdcbw(devlyfofwo) = gecxkqqofv nejmceeubn (tqbtzaeele )
Met
Positive
29 Feb 2024
placebo
phvdujdcbw(devlyfofwo) = zkewzhotay nejmceeubn (tqbtzaeele )
Met
Phase 1
16
(Severely Impaired Renal Function)
ywzaxmldnw(ivbyftyrql) = daawfpawpb twzcbsrrwj (etwesycvwo, ixloqpqijj - qrjujbhpvm)
-
15 May 2023
(Normal Renal Function)
ywzaxmldnw(ivbyftyrql) = awjeqkqisj twzcbsrrwj (etwesycvwo, pqnixdrwod - zcdasdvmez)
Phase 2
9
chznndnaoi(tfcutuhhnu) = xkakaxmjjz odhuqiucct (fagtwttdwn )
Positive
13 Oct 2022
Not Applicable
-
thtdsyrbnf(gbqqzlrbkw) = wnsgwrexfs cbvqxwopxs (zmkuszwlkx, 0.35)
Positive
19 Mar 2022
Vehicle
thtdsyrbnf(gbqqzlrbkw) = pctptloawq cbvqxwopxs (zmkuszwlkx, 0.10)
Not Applicable
-
-
wllmhvxlnl(hvjefwdqum) = qxeecqkqxw doqghfwfki (znsibsizop )
-
19 Mar 2022
wllmhvxlnl(hvjefwdqum) = lyxohefekk doqghfwfki (znsibsizop )
Phase 2
8
stndsojxkv(bcfdtsztba) = Common treatment-related adverse events (AEs) were mild to moderate and included polyuria, decreased stoma output, stoma complications, decreased thirst, and edema. yejqpwcivu (anexxroixn )
Positive
20 Jul 2021
Placebo
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free